Fangfang Li

PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo

Wenyan Wang, L. Ye, Jingwei Tian, 2019, Acta pharmaceutica Sinica. B.

Integrating network pharmacology and experimental validation to explore the effect and mechanism of AD-1 in the treatment of colorectal cancer

Yuqing Zhao, Jiawei Li, Fangfang Li, 2023, Frontiers in Pharmacology.